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55923 UNUSUAL METASTASES FROM DIFFERENTIATED THYROID CANCER
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1 Departamento de Tiroides de SAEM
Introduction: Complications related to metastatic disease are the main cause of specific mortality in patients with differentia-
ted thyroid cancer (DTC). The most common sites of metastases are lungs and bones. Other localizations are infrequent and 
they have been reported as isolated cases or small series. The impact of these unusual metastases (UM) in patient management 
and prognosis remains largely unknown. Objectives: to evaluate the prevalence of UM in DTC patients, to define their clinico-
pathological characteristics and to analyze its relevance in DTC management and mortality. Patients and methods: We retros-
pectively reviewed the file records from 7 databases. UM were diagnosed by: a) biopsy and/or b) radioiodine uptake + elevated 
thyroglobulin (Tg) levels and/or c) uptake of 18-FDG in the PET-CT scan + elevated Tg levels. We analyzed histopathologic 
characteristics, clinical presentation, localization, time of diagnosis (synchronic vs. metachronic presentation), diagnostic and 
therapeutic modalities and final outcome of patients. Results: UM were diagnosed in 29 out of 2,986 DTC patients (1%). 
The most common site of UM was the central nervous system (CNS, 31%); the second was skin (20%), followed by liver and 
non-cervicomediastinal lymph node (8% each). 21% of the patients had more than one UM. In 93% of the cases, UM coexisted 
with either lung and/or bone metastases and/or locoregional disease. Papillary histology was found in 75% of cases; 79% were 
metachronic with DTC diagnosis, and 76% fulfilled radioiodine refractoriness criteria. Half of the patients reported symptoms 
related to the UM. In 76% of the cases, therapeutic decisions were influenced by the diagnosis of the UM. Median follow-up 
after the diagnosis of UM was 16 months; 16 patients (55%) died due to DTC related causes, with a mean survival of 8.5 
months. The most frequent cause of death was CNS metastasis progression. Conclusions: UM are a rare entity in patients 
with DTC. They are usually metachronic and radioiodine refractory. UM were found in patients with widespread disease, and 
treatment strategies were modified by their diagnosis. UM were associated with poor prognosis and disease specific mortality.
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Introduction: Radioactive iodine (RAI) is widely used in the management of differentiated thyroid cancer (DTC). When RAI 
is indicated, current guidelines indicate a post-therapy whole-body scan (WBS) in order to document iodine‘s avidity of struc-
tural disease, and to update disease stage. However, the utility of the post-therapy WBS for low-risk DTC has been questioned. 
Objective: Evaluate the diagnostic value of post-therapy WBS in the population of low-risk DTC. Material and methods: 
From a cohort of 1045 DTC patients consecutively attended in Thyroid Outpatient Clinic of the Endocrine Division of Hospi-
tal de Clínicas de Porto Alegre we selected those who have undergone RAI, performed post-therapy WBS and were classified as 
low-risk according to the 2009 ATA risk system. Persistent disease was defined as the presence of clinical or radiological and/
or biochemical disease (thyroglobulin under suppression > 1 ng/mL and/or stimulated thyroglobulin > 2 ng/mL). Results: A 
total of 295 low-risk DTC patients were studied. The age at diagnosis was 46 ± 14 years, 260 (88%) women, with a tumor of 
1.8 cm (P25-P75 1.0-3.0) and 218 (74%) with TNM AJCC stage I disease. The post-operatory stimulated-Tg was 5.1 ng/dL 
(P25-P75 1.3-13.5) and the RAI activity 94 ± 30 mCi. Post-therapy WBS showed no distant metastasis in all studied patients 
(n= 0/295). At a 6 year (P25-P75 3-9) follow up, 192 (81%) patients were disease free, 36 (15%) had persistent biochemi-
cal disease and 10 (3%) structural disease, 5 (1.5%) of which had distant metastases not detected on the post-therapy WBS. 
Conclusion: In low-risk DTC patients, post-therapy WBS do not contribute to risk stratification nor to long term prognosis. 
Performing the post-therapy WBS in the low-risk population seems unnecessary, and avoiding this procedure could reduce the 
number of hospital visits and treatment costs.
